Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Pharvaris N.V.

▤ Summary

Pharvaris closed a $132.3 million underwritten offering of ordinary shares and said the underwriters fully exercised their option to buy additional shares. The company sold all shares in the offering and will use the proceeds after deducting underwriting costs and expenses. Pharvaris is a late-stage biopharmaceutical company developing oral treatments for bradykinin-mediated diseases, including hereditary angioedema. The company also said its Phase 3 work remains underway, with topline data expected in the third quarter of 2026.

$ Funding

▦ Linked Companies